Anivance AI Corporation
Anivance AI develops AI-enabled organ-on-chip and microphysiological systems to generate human-relevant preclinical data. The company combines microfluidic 3D tissue models, modular perfusion hardware, and multi-agent AI for experiment design and automation, and offers Lab-as-a-Service (LaaS) for outsourced preclinical testing and model development. Public resources and publications describe applications in pulmonary modeling, inhalation/aerosol testing, and multi-tissue disease models.
Industries
Nr. of Employees
small (1-50)
Anivance AI Corporation
Products
Perfusion microphysiological system (compact MPS)
A compact, plug-and-play perfusion platform supporting up to six chips, dual peristaltic pumps, long-term perfusion, and compatibility with standard microscopes and lab equipment.
Catalog of ready-to-run organ/tissue models
Preconfigured organ-on-chip models (lung bronchial/alveoli, liver tri-culture, kidney, skin, vascular, cancer models) optimized for specific applications such as COPD, cystic fibrosis, fibrosis, viral infection, and oncology studies.
Perfusion microphysiological system (compact MPS)
A compact, plug-and-play perfusion platform supporting up to six chips, dual peristaltic pumps, long-term perfusion, and compatibility with standard microscopes and lab equipment.
Catalog of ready-to-run organ/tissue models
Preconfigured organ-on-chip models (lung bronchial/alveoli, liver tri-culture, kidney, skin, vascular, cancer models) optimized for specific applications such as COPD, cystic fibrosis, fibrosis, viral infection, and oncology studies.
Services
On-demand execution of experiments including drug screening, preclinical toxicity prediction, and efficacy testing using microphysiological models and automated workflows.
Multi-agent AI service that generates protocols, simulates experiments, monitors runs, and produces analysis and reports to accelerate experimental cycles.
On-demand execution of experiments including drug screening, preclinical toxicity prediction, and efficacy testing using microphysiological models and automated workflows.
Multi-agent AI service that generates protocols, simulates experiments, monitors runs, and produces analysis and reports to accelerate experimental cycles.
Expertise Areas
- Organ-on-chip and microphysiological systems
- AI-driven experimental design and laboratory automation
- Preclinical model development for pulmonary and multi-organ systems
- Lab-as-a-Service for drug screening and toxicity prediction
Key Technologies
- Organ-on-chip (microfluidic 3D tissue models)
- Microphysiological perfusion systems (MPS)
- Multi-agent AI for experiment design and monitoring
- Automated workflow orchestration
News & Updates
Participation in SWITCH 2025 exhibition.
Exhibition participation at AACR Annual Meeting 2025.
Exhibition participation at Medical Taiwan 2025.
Company selected as a Top 30 finalist for VivaTech Innovation of the Year 2025.
Selected as one of the Top 30 finalists for VivaTech Innovation of the Year 2025.
Received Moderna Taiwan mRNA Innovation Award in 2023.
Participation in SWITCH 2025 exhibition.
Exhibition participation at AACR Annual Meeting 2025.
Exhibition participation at Medical Taiwan 2025.
Company selected as a Top 30 finalist for VivaTech Innovation of the Year 2025.
Selected as one of the Top 30 finalists for VivaTech Innovation of the Year 2025.
Received Moderna Taiwan mRNA Innovation Award in 2023.